Please assess the completion status of the following clinical trial:

Trial Title: Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years or older~2. Diagnosis of Polycythemia Vera according to the WHO 2008 criteria (Barbui et al, 2011) with the mandatory presence of JAK2V617F mutation as the major disease criterion.~3. For previously cytoreduction untreated patients - documented need of cytoreductive treatment~   - leukocytosis (WBC\>10G/L for two measurements within one week)~4. For patients currently treated or pre-treated with HU, all of the following criteria:~   * being non responders (as defined by the response criteria for primary endpoint)~  * total HU treatment duration shorter than three years~  * no documented resistance or intolerance as defined by modified Barosi et al, 2009 criteria~5. Hospital Anxiety and Depression Scale (HADS) score 0-7 on both subscales~6. Patients with HADS score of 8-10 inclusive on either or both of the subscales may be eligible following psychiatric assessment that excludes clinical significance of the observed symptoms in the context of potential treatment with an interferon alpha~7. Signed written informed consent~Exclusion Criteria:~1. Any systematic cytoreduction for PV prior study entry with exception of HU for shorter than 3 years (see respective inclusion criterion)~2. Any contraindication to any of the IMPs (pegylated interferon or hydroxyurea) or their excipients~3. Any systemic exposure to a non-pegylated or pegylated interferon alpha~4. Documented autoimmune disease at screening or in the medical history~5. Clinically relevant pulmonary infiltrates, pneumonia, and pneumonitis at screening~6. Systemic infections, e.g. hepatitis B, hepatitis C, or HIV at screening~7. Known PV-related thromboembolic complications in the abdominal area (e.g. portal vein thrombosis, Budd-chiari syndrome) and/or splenectomy in the medical history~8. Any investigational drug less than 6 weeks prior to the first dose of study drug or not recovered from effects of prior administration of any investigational agent~9. History or presence of depression requiring treatment with antidepressant~10. HADS score equal to or above 11 on either or both of the subscales~11. Any risk of suicide at screening or previous suicide attempts~12. Any significant morbidity or abnormality which may interfere with the study participation~13. Pregnancy and breast-feeding females of reproductive potential and males not using effective means of contraception~14. History of active substance or alcohol abuse within the last year~15. Evidence of severe retinopathy (e.g. cytomegalovirus retinitis, macular degeneration) or clinically relevant ophthalmological disorder (due to diabetes mellitus or hypertension)~16. Thyroid dysfunction not adequately controlled~17. Patients tested positively with TgAb and / or TPOAb at screening~18. History of major organ transplantation~19. History of uncontrolled severe seizure disorder~20. Leukocytopenia at the time of screening~21. Thrombocytopenia at the time of screening~22. History of malignant disease, including solid tumours and hematological malignancies (except basal cell and squamous cell carcinomas of the skin and carcinoma in situ of the cervix that have been completely excised and are considered cured) within the last 3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydroxyurea (Type: ACTIVE_COMPARATOR): Hydroxyurea capsules (500 mg each). Daily intake of doses from 500 mg Q2D to 3000 mg QD
- Peg-P-IFN-alpha-2b (AOP2014) (Type: EXPERIMENTAL): Peg-P-IFN-alpha-2b at 50mcg to max 500 mcg, given every other week as one subcutanous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).